New cocktail of drugs shows promise for Hard-to-Treat stomach cancers
NCT ID NCT05394740
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of two targeted drugs (regorafenib and nivolumab) plus standard chemotherapy in 30 adults with advanced or recurrent stomach, gastroesophageal junction, or esophageal adenocarcinoma that could not be surgically removed. The goal was to see if the combination was safe and could shrink tumors. Results may help design larger studies, but the small size and lack of a comparison group mean the findings are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- regorafenib (Stivarga) and nivolumab (Opdivo) plus chemotherapy (CapeOX or FOLFOX)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced stomach or esophageal cancer that cannot be removed by surgery.
- What could go wrong
- This is a small, early-phase trial (30 participants) with no control group, so results may not apply to everyone. The combination also carries risks of side effects from multiple drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?